newsfilter
← Latest News
GlobeNewswire·

Scopus BioPharma Launches Duet Therapeutics

Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021 Integration Creates Comprehensive, Industry-Leading Portfolio of Bi-Functional Cancer-Targeting Oligonucleotides NEW YORK, Sept.